Find your path to Dean
29 people in our graph share verified history with Dean — schools, employers, funds. One of them is your warm intro.
About
Dean Slagel is Managing Director at Marom Advisory Partners and was the founding Managing Director of Esperante Ventures, where he oversaw investments of EUR 500k–5m in mid-to-late stage therapeutics and commercial-stage diagnostics across North America, Europe and Israel. His track record includes 25+ portfolio investments, five exits and four public listings, among them the IPOs of Cara Therapeutics, Altimmune and Medicenna Therapeutics, and he has served as investor or non-executive director on nine biotech boards. Earlier, he held business development roles at Ferring Pharmaceuticals in Paris and Copenhagen and at Tillotts Pharma in Basel, covering licensing and international market development in regions including Mexico, Russia, Israel, Saudi Arabia and Canada.
Contact· self-published, not guessed
Experience
- Marom Advisory PartnersManaging Directorcurrent2026 — presentGreater London, England, United Kingdom
- Esperante VenturesManaging Director2004 — 2026London Area, United Kingdom
- Ferring PharmaceuticalsGlobal Business Development Director2001 — 2003Greater Paris Metropolitan Region
- Ferring PharmaceuticalsProject Director, International Business Development & Regional Management1995 — 2001Greater Paris Metropolitan Region
- Tillotts Pharma AGInternational Marketing Director1991 — 1995Basel, Basel, Switzerland
Skills & more
+11 more
Venture CapitalLifesciencesStart-upsPharmaceuticsManagementBiotechnologyPharmaceutical IndustryCorporate DevelopmentStrategyDue DiligenceTechnology TransferLanguages English · French · German
- MBA
From Dean's professional profile.
Frequently asked questions
- Who is Dean Slagel?
- Dean Slagel is Managing Director at Marom Advisory Partners and was the founding Managing Director of Esperante Ventures, where he oversaw investments of EUR 500k–5m in mid-to-late stage therapeutics and commercial-stage diagnostics across North America, Europe and Israel. His track record includes 25+ portfolio investments, five exits and four public listings, among them the IPOs of Cara Therapeutics, Altimmune and Medicenna Therapeutics, and he has served as investor or non-executive director on nine biotech boards. Earlier, he held business development roles at Ferring Pharmaceuticals in Paris and Copenhagen and at Tillotts Pharma in Basel, covering licensing and international market development in regions including Mexico, Russia, Israel, Saudi Arabia and Canada.
- Where does Dean Slagel work?
- Dean Slagel is Managing Director at Esperante Ventures.
- Where did Dean Slagel go to school?
- Dean Slagel studied at École des Ponts Business School (Master of Business Administration); St Albans School.
Same school
Also attended École des Ponts Business School9
+ 3 more
Also attended St Albans School11
+ 5 more
Shared employers
Also worked at Ferring Pharmaceuticals10
+ 4 more